Skip to content
银诺医药 INNOGEN
HKEX 02591
CareersContact
Company

Company

View overview →
Vision & mission→Leadership→Our history→Institutional investors→
Science & pipeline

Science & pipeline

View overview →
Development pipeline→Clinical evidence→Protein platform→Development & manufacturing→Research library→
Medicine resources
Investors

Latest results2026.08.25

2026 interim results announcement

Six months ended 30 June 2026

EnglishPDF ↗繁體中文PDF ↗
Investor overview →
Financial reports→Announcements & circulars→Governance→Listing documents→Corporate communications→IR contact→
News
EN中文
Company→Science & pipeline→Medicine resources→Investors→News→
CareersContact
← About Innogen

Institutional investors

Profiles published in 2022.

BioTrack Capital

View profile →

Dyee Capital

View profile →

China Everbright Limited

View profile →

Hongtai Fund

View profile →

China Growth Capital

View profile →

Guoke Jiahe (Beijing) Investment Management

View profile →

Korea Investment Partners (KIP)

View profile →

Langmafeng Venture Capital

View profile →

Shanghai Pudong Investment Holdings (Group) Co., Ltd.

View profile →

Cowin Capital

View profile →

Xiaochi Capital

View profile →

Youshan Capital (优山资本)

View profile →

V Star Capital

View profile →

Yuanhui Chuangyi

View profile →

CICC Capital

View profile →

Centurium Capital

For current shareholding information, see our investor disclosures.

银诺医药 INNOGEN

Focused on diabetes and metabolic diseases

HKEX 02591
CompanyScience & pipelineMedicine resourcesInvestorsNewsCareersContact

Contact Innogen

Follow Innogen on WeChat
QR code to follow Innogen on WeChat

Scan with WeChat.

Save QR code
info@innogenpharm.com ↗

399 Haiyang West Road, Pudong, Shanghai
21st Floor, Qiantan Times Square

Adverse events, complaints and inquiries400-004-0060
Drug_safety.postmarketing@innogenpharm.com ↗
© 2026 Innogen
Original site ICP: 沪ICP备16021048号-1 ↗
Website recreation previewInformation & sources
Institutional investors · Innogen